key: cord-0939379-anz49bic authors: Garg, Heena; Khanna, Puneet title: Covid and cholesterol (C&C): Something to worry about or much ado about nothing? date: 2020-09-16 journal: nan DOI: 10.1016/j.tacc.2020.09.003 sha: c8310c515a4749d9625398b92c56a18a06418158 doc_id: 939379 cord_uid: anz49bic nan (VLDL), low-density lipoprotein (LDL)) along with reduced high-density lipoprotein levels (HDL), has been postulated as a possible exacerbating factor indicating poor outcomes by dysregulating protective immunity and promoting exaggerated pulmonary and systemic inflammatory responses. [1] COVID-19 is an RNA virus having a lipid envelope. Hence, cholesterol biosynthesis pathways play an important role in the assembly, replication and infectivity of these viral particles. [2] Cholesterol-modifying drugs, mainly statins, have been hypothesized to have antiviral effects. These drugs decrease the synthesis, systemic absorption of cholesterol or exhibit direct antiviral activity altering the target cell membrane cholesterol. Statins also have additional non-lipid-related pleiotropic effects. This includes improved endothelial function, atherosclerotic plaques stabilization, anti-inflammatory, immunomodulatory and antithrombotic effects. [3, 4] These additional properties of statins might confer a possible benefit in patients infected with COVID-19. Radenkovic et al [1] recommended that patients already on statins should continue taking it if diagnosed COVID positive. In high-risk patients having severe COVID-19 disease, statin therapy may be initiated to prevent life-threatening cardiovascular complications. The major reason for discontinuation of statin therapy is statin-associated muscle symptoms. Statin therapy needs to be discontinued in skeletal muscle symptoms and elevated liver enzymes. [3] LDL contributes to vasculopathy in patients with COVID-19. The virus invades the endothelial cells (EC) and causes acute endothelial injury and triggers coagulopathies as significant clinical sequelae. The ECs within atherosclerotic plaques are more vulnerable to an attack from COVID-19 or inflammatory storms, causing a rupture of plaques and a high risk of developing coagulopathy in patients with associated cardiovascular preconditions. Cao et al suggested that hyperlipidaemia is a significant contributor to endothelial dysfunction J o u r n a l P r e -p r o o f leading to atherosclerosis. They recommended lowering LDL levels using statins to ameliorate the degree of vasculopathy and protect the endothelial integrity from COVID-19 attack. [5] However, Wei et al [6] , in their retrospective study, assessed the serum levels of LDL, HDL, and TC in 597 COVID-19 patients and found significantly lower levels of LDL and TC as compared with normal subjects. They also observed that HDL levels decreased significantly only in critical cases as compared to the levels in mild and severe cases. They postulated several mechanisms for this including decreased LDL biosynthesis due to liver dysfunction, altered lipid metabolism due to acute inflammation, elevated free radicals causing lipid degradation and altered vascular permeability causing a leakage of cholesterol molecules into tissues. Hu et al [7] , observed a similar trend with sharply decreased total cholesterol (TC), HDL and LDL levels. They also observed that HDL level was significantly lower in the patients with COVID-19 primary infection than secondary infection patients. HDL is an anti-inflammatory lipoprotein with protective effects against oxidized lipids. Due to this, they speculated that serum HDL-cholesterol was involved in the regulation of immune cells during COVID-19 infection, which might lead to the significantly dropped HDL-cholesterol level in the patients. Zhu et al [8] analysed the blood lipid profile and predictive values in 142 patients with COVID-19 ranging from healthy controls to severely affected (17 cases). They corroborated the findings where TC, HDL, LDL and apolipoprotein A1 (ApoA1) gradually decreased across healthy controls, non-severe group, and severe group. They recognised ApoA1 as an independent risk factor for COVID-19 severity. Cholesterol in Relation to COVID-19: Should We Care about It? Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? Statin Toxicity Cholesterol-modifying drugs in COVID-19 Cholesterol: A new game player accelerating vasculopathy caused by SARS-CoV-2? Hypolipidemia is associated with the severity of COVID-19 Low Serum Cholesterol Level Among Patients with COVID-19 Infection in Wenzhou, China A Preliminary Study on Blood Lipid Profile in Patients with COVID-19. PREPRINT (Version 1) available at Research Square 14 Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019 COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches Cholesterol-lowering treatment may be a major cause of serious Covid-12 Are certain drugs associated with enhanced mortality in COVID-19? Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19). Diabetes & metabolic syndrome Proteomics of SARS-CoV-2-infected host cells reveals therapy targets Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19 FEnofibRate as a Metabolic INtervention for Coronavirus Disease Proteomic and Metabolomic Characterization of COVID-19 Low serum level of apolipoprotein A1 is an indicator of severity in patients with coronavirus disease 2019 The Potential Beneficial Effect of EPA and DHA Supplementation Managing Cytokine Storm in Coronavirus Disease